Quantitative rat liver function test by galactose single point method

Laboratory Animals

Volumn 42, Issue 4, 2008, Pages 495-504

  Young, T H ^a,b   Tang, H S ^b   Chao, Y C ^c   Lee, H S ^c   Hsiong, C H ^a   Pao, L H ^a   Hu, O Y P ^a  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^c TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Galactose single point method; Hepatotoxicity; Isoniazid; Quantitative liver function; Rat

Indexed keywords

4 NITROPHENYL PHOSPHATE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CARBON TETRACHLORIDE; GALACTOSE; ISONIAZID;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; ENZYME ACTIVITY; FOOD AND DRUG ADMINISTRATION; LIVER FUNCTION TEST; LIVER TOXICITY; MALE; MICROPHOTOGRAPHY; MICROSCOPY; NONHUMAN; QUANTITATIVE ANALYSIS; RAT;

ALANINE TRANSAMINASE; ANIMALS; ANIMALS, LABORATORY; ASPARTATE AMINOTRANSFERASES; CARBON TETRACHLORIDE; GALACTOSE; HISTOCYTOCHEMISTRY; ISONIAZID; LIVER; LIVER DISEASES; LIVER FUNCTION TESTS; MALE; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA; RATTUS;

EID: 55049122089     PISSN: 00236772     EISSN: None     Source Type: Journal    
DOI: 10.1258/la.2007.06040e     Document Type: Article

References (43)

1. Baker AL, Kotake AN, Schoeller DA (1983) Clinical utility of breath tests for the assessment of hepatic function. Seminars in Liver Disease 3, 318-29
2. Ballard FJ (1966) Purification and properties of galactokinase from pig liver. Biochemical Journal 98, 347-52
3. Becker M (1998) 13C breath test for measurement of liver function. Gut 43 (suppl. 3), S25-7
4. Bircher J (1986) Assessment of prognosis in advanced liver disease: to score or to measure, that's the question. Hepatology 6, 1036-7
5. Boone L, Mever D, Cusick P, et al. (2005) Selection and interpretation of clinical pathology indicators of hepatic injury in preclinical studies. Veterinary Clinical Pathology 34, 182-8
6. Bruckner JV, MacKenzie WF, Muralidhara S, Luthra R, Kyle GM, Acosta D (1986) Oral toxicity of carbon tetrachloride: acute, subacute, and subchronic studies in rats. Fundamental and Applied Toxicology 6, 16-34
7. Chopra P, Roy S, Ramalingaswami V, Nayak NC (1972) Mechanism of carbon tetrachloride hepatotoxicity. An in vivo study of its molecular basis in rats and monkeys. Laboratory Investigation 26, 716-27
8. Craik JD, Elliott KR (1980) Transport of D-fructose and D-galactose into isolated rat hepatocytes. Biochemical Journal 192, 373-5
9. Diepenbrock F, Heckler R, Schickling H, Engelhard T, Bock D, Sander J (1992) Colorimetric determination of galactose and galactose-1-phosphate from dried blood. Clinical Biochemistry 25, 37-9
10. Food and Drug Administration (2003) Guidance for Industry: Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling. US Department of Health and Human Services, FDA, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research
11. Fujii T (1997) Toxicological correlation between changes in blood biochemical parameters and liver histopathological findings. Journal of Toxicological Sciences 22, 161-83
12. Fujimura Y, Ishii S, Kawamura M, Naruse H (1981) Microdetermination of galactose and galactose 1-phosphate in dried blood spots. Analytical Biochemistry 117, 187-95
13. Henderson JM, Kutner MH, Bain RP (1982) First-order clearance of plasma galactose: the effect of liver disease. Gastroenterology 83, 1090-6
14. Henry RJ, Chiamori N, Golub OJ, Berkman S (1960) Revised spectrophotometric methods for the determination of glutamic-oxalacetic transaminase, glutamic-pyruvic transaminase, and lactic acid dehydrogenase. American Journal of Clinical Pathology 34, 381-98
15. Homeida M, Roberts CJ, Halliwell M, Read AE, Branch RA (1979) Antipyrine clearance per unit volume liver: an assessment of hepatic function in chronic liver disease. Gut 20, 596-601
16. Hu OY, Hu TM, Tang HS (1995a) Determination of galactose in human blood by high-performance liquid chromatography: comparison with an enzymatic method and application to the pharmacokinetic study of galactose in patients with liver dysfunction. Journal of Pharmaceutical Sciences 84, 231-5
17. Hu OY, Tang HS, Chang CL (1995b) Novel galactose single point method as a measure of residual liver function: example of cefoperazone kinetics in patients with liver cirrhosis. Journal of Clinical Pharmacology 35, 250-8
18. Hu OY, Tang HS, Sheeng TY, Chen TC, Curry SH (1995c) Pharmacokinetics of promazine in patients with hepatic cirrhosis - correlation with a novel galactose single point method. Journal of Pharmaceutical Sciences 84, 111-14
19. Hu OY, Tang HS, Chang CL (1994) The influence of chronic lobular hepatitis on pharmacokinetics of cefoperazone - a novel galactose single-point method as a measure of residual liver function. Biopharmaceutics and Drug Disposition 15, 563-76
20. Huang YS, Chern HD, Su WJ, et al. (2003) Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 37, 924-30
21. Keiding S (1973) Galactose elimination capacity in the rat. Scandinavian Journal of Clinical and Laboratory Investigation 31, 319-25
22. Keiding S, Johansen S, Tonnesen K (1977) Kinetics of ethanol inhibition of galactose elimination in perfused pig liver. Scandinavian Journal of Clinical and Laboratory Investigation 37, 487-94
23. Keiding S, Johansen S, Winkler K (1982) Hepatic galactose elimination kinetics in the intact pig. Scandinavian Journal of Clinical and Laboratory Investigation 42, 253-9
24. Knodell RG, Ishak KG, Black WC, et al. (1981) Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1, 431-5
25. Lee WM (1995) Drug-induced hepatotoxicity. New England Journal of Medicine 333, 1118-27
26. Lindskov J (1982) The quantitative liver function as measured by the galactose elimination capacity. I. Diagnostic value and relations to clinical, biochemical, and histological findings in patients with steatosis and patients with cirrhosis. Acta Medica Scandinavica 212, 295-302
27. Mitchell JR, Zimmerman HJ, Ishak KG, et al. (1976) Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Annals of Internal Medicine 84, 181-92
28. O'Brien PJ, Slaughter MR, Polley SR, Kramer K (2002) Advantages of glutamate dehydrogenase as a blood biomarker of acute hepatic injury in rats. Laboratory Animals 36, 313-21
29. O'Brien PJ, Slaughter MR, Swain A, et al. (2000) Repeated acetaminophen dosing in rats: adaptation of hepatic antioxidant system. Human and Experimental Toxicology 19, 277-83
30. Orfanos AP, Jinks DC, Guthrie R (1986) Microassay for estimation of galactose and galactose-1-phosphate in dried blood specimens. Clinical Biochemistry 19, 225-8
31. Provost JP, Hanton G, Le Net JL (2003) Plasma triglycerides: an overlooked biomarker of hepatotoxicity in the rat. Comparative Clinical Pathology 12, 95-101
32. Renner E, Wietholtz H, Huguenin P, Arnaud MJ, Preisig R (1984) Caffeine: a model compound for measuring liver function. Hepatology 4, 38-46
33. Roberts RK, Wilkinson GR, Branch RA, Schenker S (1978) Effect of age and parenchymal liver disease on the disposition and elimination of chlordiazepoxide (librium). Gastroenterology 75, 479-85
34. Sarich TC, Adams SP, Petricca G, Wright JM (1999) Inhibition of isoniazid-induced hepatotoxicity in rabbits by pretreatment with an amidase inhibitor. Journal of Pharmacology and Experimental Therapeutics 289, 695-702
35. Sarich TC, Youssefi M, Zhou T, Adams SP, Wall RA, Wright JM (1996) Role of hydrazine in the mechanism of isoniazid hepatotoxicity in rabbits. Archives of Toxicology 70, 835-40
36. Sodhi CP, Rana SV, Mehta SK, et al. (1996) Study of oxidative stress in isoniazid-induced hepatic injury in young rats with and without protein-energy malnutrition. Journal of Biochemical Toxicology 11, 139-46
37. Tang HS, Hu OY (1992) Assessment of liver function using a novel galactose single point method. Digestion 52, 222-31
38. Tygstrup N (1964) The galactose elimination capacity in control subjects and in patients with cirrhosis of the liver. Acta Medica Scandinavica 175, 281-9
39. Weingand K, Brown G, Hall R, et al. (1996) Harmonization of animal clinical pathology testing in toxicity and safety studies. Fundamental and Applied Toxicology 29, 198-201
40. Wu JC, Lee SD, Yeh PF, et al. (1990) Isoniazid-rifampin-induced hepatitis in hepatitis B carriers. Gastroenterology 98, 502-4
41. Yamaguchi A, Fukushi M, Mizushima Y, et al. (1989) Microassay for screening newborns for galactosemia with use of a fluorometric microplate reader. Clinical Chemistry 35, 1962-4
42. Yamamoto T, Suou T, Hirayama C (1986) Elevated serum aminotransferase induced by isoniazid in relation to isoniazid acetylator phenotype. Hepatology 6, 295-8
43. Yue J, Peng RX, Yang J, Kong R, Liu J (2004) CYP2E1 mediated isoniazid-induced hepatotoxicity in rats. Acta Pharmacologica Sinica 25, 699-704